Arcturus Therapeutics Holdings Stock Market Value
| ARCT Stock | USD 7.23 0.02 0.28% |
| Symbol | Arcturus |
Is there potential for Biotechnology market expansion? Will Arcturus introduce new products? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
Understanding Arcturus Therapeutics requires distinguishing between market price and book value, where the latter reflects Arcturus's accounting equity. The concept of intrinsic value - what Arcturus Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Arcturus Therapeutics' price substantially above or below its fundamental value.
Understanding that Arcturus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Arcturus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Arcturus Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Arcturus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Arcturus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Arcturus Therapeutics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Arcturus Therapeutics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Arcturus Therapeutics Holdings or generate 0.0% return on investment in Arcturus Therapeutics over 90 days. Arcturus Therapeutics is related to or competes with Sagimet Biosciences, Humacyte, Voyager Therapeutics, Entrada Therapeutics, Vanda Pharmaceuticals, Achieve Life, and Foghorn Therapeutics. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, an... More
Arcturus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Arcturus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Arcturus Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 15.98 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.53 |
Arcturus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arcturus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Arcturus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Arcturus Therapeutics historical prices to predict the future Arcturus Therapeutics' volatility.| Risk Adjusted Performance | (0.04) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.10) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Arcturus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Arcturus Therapeutics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.09) | |||
| Mean Deviation | 2.88 | |||
| Coefficient Of Variation | (1,696) | |||
| Standard Deviation | 3.83 | |||
| Variance | 14.69 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.10) | |||
| Maximum Drawdown | 15.98 | |||
| Value At Risk | (6.44) | |||
| Potential Upside | 6.53 | |||
| Skewness | 0.3283 | |||
| Kurtosis | 0.6222 |
Arcturus Therapeutics Backtested Returns
Arcturus Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Arcturus Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0562, which signifies that the company had a 0.0562 % return per unit of standard deviation over the last 3 months. We have found twenty-three technical indicators for Arcturus Therapeutics Holdings, which you can use to evaluate the volatility of the firm. Please makes use of Arcturus Therapeutics' risk adjusted performance of (0.04), and Mean Deviation of 2.88 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Arcturus Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 2.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arcturus Therapeutics will likely underperform. Please check Arcturus Therapeutics' potential upside, and the relationship between the jensen alpha and rate of daily change , to make a quick decision on whether Arcturus Therapeutics' price patterns will revert.
Auto-correlation | 0.36 |
Below average predictability
Arcturus Therapeutics Holdings has below average predictability. Overlapping area represents the amount of predictability between Arcturus Therapeutics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Arcturus Therapeutics price movement. The serial correlation of 0.36 indicates that just about 36.0% of current Arcturus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.36 | |
| Spearman Rank Test | -0.24 | |
| Residual Average | 0.0 | |
| Price Variance | 0.13 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.